PMID- 19147454
OWN - NLM
STAT- MEDLINE
DCOM- 20090319
LR  - 20220318
IS  - 1388-9842 (Print)
IS  - 1388-9842 (Linking)
VI  - 11
IP  - 1
DP  - 2009 Jan
TI  - Bone mineral status and bone loss over time in men with chronic systolic heart 
      failure and their clinical and hormonal determinants.
PG  - 28-38
LID - 10.1093/eurjhf/hfn004 [doi]
AB  - AIMS: Bone status has not been comprehensively studied in chronic heart failure 
      (CHF). In CHF men, we evaluated bone status, bone loss over time, and their 
      clinical and hormonal determinants. METHODS AND RESULTS: Bone mineral content 
      (BMC) and bone mineral density (BMD) of arms, legs, trunk, and total body were 
      examined using dual-energy X-ray absorptiometry in 187 men with CHF [age: 60+/-11 
      years, left ventricular ejection fraction (LVEF): 32+/-7%, New York Heart 
      Association (NYHA) class (I/II/III/IV): 20/76/76/15] and in 21 age-matched male 
      controls without CHF. Men with CHF had reduced BMD and BMC compared with controls 
      (P < 0.05). Reduced BMD and BMC were independently determined by CHF severity 
      (high NYHA class and impaired LVEF), reduced lean tissue mass, low serum 
      dehydroepiandrosterone sulphate, total testosterone (TT), and estimated free 
      testosterone (eFT) (all P < 0.05). Bone status was reassessed in 60 patients who 
      survived >2 years from the initial evaluation. Significant bone loss over time (a 
      reduction in BMC total > or = 1%/year) occurred in 35% of CHF men. Advanced NYHA 
      class (P < 0.05) and reduced serum TT and eFT (P < 0.0001) at baseline predicted 
      augmented bone loss. CONCLUSION: In CHF men, reduced BMD and BMC constitute an 
      element of generalized body wasting, determined mainly by advanced heart failure 
      and androgen deficiencies. Significant bone loss over time frequently occurs in 
      CHF men and is related to testosterone depletion and disease severity.
FAU - Jankowska, Ewa A
AU  - Jankowska EA
AD  - Cardiology Department, Military Hospital, ul. Weigla 5, 50-981 Wroclaw, Poland. 
      ewa.jankowska@antro.pan.wroc.pl
FAU - Jakubaszko, Justyna
AU  - Jakubaszko J
FAU - Cwynar, Aldona
AU  - Cwynar A
FAU - Majda, Jacek
AU  - Majda J
FAU - Ponikowska, Beata
AU  - Ponikowska B
FAU - Kustrzycka-Kratochwil, Dorota
AU  - Kustrzycka-Kratochwil D
FAU - Reczuch, Krzysztof
AU  - Reczuch K
FAU - Borodulin-Nadzieja, Ludmila
AU  - Borodulin-Nadzieja L
FAU - Banasiak, Waldemar
AU  - Banasiak W
FAU - Poole-Wilson, Philip A
AU  - Poole-Wilson PA
FAU - Ponikowski, Piotr
AU  - Ponikowski P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
RN  - 3XMK78S47O (Testosterone)
RN  - 57B09Q7FJR (Dehydroepiandrosterone Sulfate)
SB  - IM
MH  - Aged
MH  - Bone Density
MH  - Chronic Disease
MH  - Dehydroepiandrosterone Sulfate
MH  - Female
MH  - Heart Failure/*physiopathology
MH  - Heart Failure, Systolic/*physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Testosterone/blood
EDAT- 2009/01/17 09:00
MHDA- 2009/03/20 09:00
CRDT- 2009/01/17 09:00
PHST- 2009/01/17 09:00 [entrez]
PHST- 2009/01/17 09:00 [pubmed]
PHST- 2009/03/20 09:00 [medline]
AID - hfn004 [pii]
AID - 10.1093/eurjhf/hfn004 [doi]
PST - ppublish
SO  - Eur J Heart Fail. 2009 Jan;11(1):28-38. doi: 10.1093/eurjhf/hfn004.